BOSTON--(BUSINESS WIRE)--HighVista Strategies LLC (“HighVista”), an alternative asset manager investing in private and public markets, today announced the completion of its acquisition of the U.S. private markets business of abrdn Inc. (“abrdn”), abrdn plc’s US subsidiary, including the U.S. private equity and venture capital assets, and the investment and operational teams. HighVista now manages approximately $9 billion of client assets. Terms of the transaction were not disclosed.
“HighVista has a singular focus on specialized alternative investments in less efficient markets,” says André Perold, CIO, co-founder and partner at HighVista Strategies. “The addition of the private equity and venture capital teams is strategic for HighVista and further solidifies our well-differentiated investment capabilities.”
Kirsten Morin and Peter Mooradian, previously co-heads of abrdn’s global venture capital investments, will manage HighVista’s venture capital strategy, with industry veteran Peter Lawrence moving into the role of a Senior Advisor. The former abrdn U.S. private equity team, including John Dickie, Scott Reed, Whit Matthews, Rob Nagle and Ryan Tiffany, will manage HighVista’s U.S. private equity strategy.
Please see the initial announcement for additional information about the transaction. Biographies for the executives joining HighVista Strategies can be viewed here.
About HighVista Strategies LLC
HighVista Strategies LLC is an employee-owned alternative asset manager that brings investors alpha opportunities in structurally inefficient markets. Based in Boston and founded in 2004, HighVista manages approximately $9 billion of capital on behalf of sophisticated investors globally. Our unique culture combines inquisitive thinking with rigorous discipline, enabling us to identify and execute on opportunities with high conviction. HighVista is a preferred partner for investors looking beyond the standard playbook for differentiated ideas that can amplify returns. HighVista’s investment strategies span private markets, including opportunistic private credit, lower middle market private equity and early-stage venture capital; public markets, including biotechnology equities and hedged public markets strategies; as well as multi-strategy alternatives. For more information, please see: https://www.highvistastrategies.com/
